OpenAI says it's adding Orchestra's team and technology to work on Rosalind, its AI model for life sciences research, and to ...
Traders poured tens of millions into a triple-leveraged biotech fund in a single day, a move that looks like bold conviction ...
Biotechnology commercialization is gaining momentum through investments such as Eli Lilly’s planned Huntsville facility and ...
HUNTSVILLE, Ala. — Huntsville is building a biotech economy, and the city will need a larger workforce with specialized ...
Germany’s Merck KGaA is paying a hefty premium to acquire Silence Therapeutics in an all-cash deal for its gene-silencing ...
Billionaire investor Cathie Wood, through her ARK ETFs, made big buys of CRISPR Therapeutics on Friday, Oct. 9, and Monday, ...
VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, presented its first in vivo ...
Biotechs must now adopt new commercial models if breakthrough treatments are to reach the patients they’re designed to help.
Recent U.S. Food and Drug Administration interactions have provided the opportunity to initiate a pivotal expansion of the ...
Despite an uptick in dealmaking and IPOs, a selective funding market and scientific setbacks are still pushing some biotechs ...
China is proposing new restrictions on foreign acquisitions of critical biopharma technologies, as the country seeks to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results